|
Abnormality of the liver
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acute Cerebrovascular Accidents
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease.
|
19433014 |
2009 |
|
Acute Chest Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
Univariate analyses showed that gender, diabetes, Apolipoprotein A1 (ApoA1) and high-density lipoprotein cholesterol (HDL-c), and diagnosis of acute coronary syndrome (ACS) were associated with plaque vulnerability (P all < 0.05).
|
30984786 |
2019 |
|
Acute Chest Syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of ApoA-I (195 vs. 161.4mg/dL; P<.001) and ApoB (167 vs. 136.9mg/dL; P<.001) were significantly higher in CS compared with ACS; however, there was no genetic association.
|
28992985 |
2018 |
|
Acute Coronary Syndrome
|
0.060 |
Biomarker
|
disease |
BEFREE |
Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes.
|
31324073 |
2019 |
|
Acute Coronary Syndrome
|
0.060 |
Biomarker
|
disease |
BEFREE |
Univariate analyses showed that gender, diabetes, Apolipoprotein A1 (ApoA1) and high-density lipoprotein cholesterol (HDL-c), and diagnosis of acute coronary syndrome (ACS) were associated with plaque vulnerability (P all < 0.05).
|
30984786 |
2019 |
|
Acute Coronary Syndrome
|
0.060 |
Biomarker
|
disease |
LHGDN |
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
|
19122170 |
2009 |
|
Acute Coronary Syndrome
|
0.060 |
Biomarker
|
disease |
BEFREE |
Recent evidence from a double-blind, randomized study showed that treatment with apolipoprotein A-I Milano (ApoA-I Milano) in a complex with phospholipids produced significant regression of the coronary atheroma burden in patients with acute coronary syndromes.
|
16039279 |
2005 |
|
Acute Coronary Syndrome
|
0.060 |
Biomarker
|
disease |
BEFREE |
APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness.
|
28992985 |
2018 |
|
Acute Coronary Syndrome
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Higher levels of apolipoprotein A-I early in life might reduce the risk of acute coronary syndromes.
|
8176109 |
1994 |
|
Acute Lung Injury
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation.
|
20972769 |
2011 |
|
Acute monocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, the RCT function of RBCs was assessed using cholesterol efflux capacity (CEC) assays, in which [3H]-labeled cholesterol-loaded human acute monocytic leukemia (THP-1) macrophages were incubated with RBCs as a cholesterol acceptor in the presence or absence of HDL or its main component protein apolipoprotein A-I (apoA-I).
|
31188743 |
2019 |
|
Acute myocardial infarction
|
0.060 |
Biomarker
|
disease |
BEFREE |
CSL112 (Apolipoprotein A-I [Human]), an infusible, plasma-derived apolipoprotein A-I, is being developed to reduce cardiovascular events following acute myocardial infarction (AMI).
|
29582212 |
2018 |
|
Acute myocardial infarction
|
0.060 |
Biomarker
|
disease |
BEFREE |
CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early recurrent cardiovascular events after acute myocardial infarction.
|
29437574 |
2018 |
|
Acute myocardial infarction
|
0.060 |
Biomarker
|
disease |
BEFREE |
CSL112 (apolipoprotein A-I [human]) is a plasma-derived apolipoprotein A-I developed for early reduction of cardiovascular risk following an acute myocardial infarction (AMI).
|
30580130 |
2019 |
|
Acute myocardial infarction
|
0.060 |
Biomarker
|
disease |
BEFREE |
CSL112 (Apolipoprotein A-I [human]) is an intravenous preparation of apolipoprotein A-I (apoA-I), formulated with phosphatidylcholine (PC) and stabilized with sucrose, in development to prevent early recurrent cardiovascular events following acute myocardial infarction (AMI).
|
30240132 |
2019 |
|
Acute myocardial infarction
|
0.060 |
Biomarker
|
disease |
BEFREE |
PTX3, HbAlc and ApoA1/apoB have a certain clinical significance in assessing the severity of AMI combined with T2DM.
|
29731826 |
2018 |
|
Acute myocardial infarction
|
0.060 |
Biomarker
|
disease |
BEFREE |
ApoB and apoA1 were higher among patients in the upper versus lower tertiles of VA. During a median of 4.6 (3.6, 5.7) years of follow-up, 8.2% of patients experienced an AMI.
|
28774484 |
2017 |
|
Acute pancreatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The AUCs of APO A-I, HDL-C, the combination of APO A-I and BISAP, or the combination of APO A-I and MCTSI to predict persistent OF among Moderately severe acute pancreatitis (MSAP) and Severe acute pancreatitis (SAP) patients were 0.886, 0.811, 0.912, and 0.900 or among those with organ failure were 0.915, 0.859, 0.933, and 0.933, respectively.
|
29183667 |
2018 |
|
Adenocarcinoma
|
0.310 |
Biomarker
|
group |
CTD_human |
Diverse proteomic alterations in gastric adenocarcinoma.
|
15378696 |
2004 |
|
Adenocarcinoma
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Expression of apolipoprotein A1 in colonic adenocarcinoma.
|
14666619 |
2003 |
|
Adenocarcinoma of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of apolipoprotein A1 in colonic adenocarcinoma.
|
14666619 |
2003 |
|
Adenocarcinoma of lung (disorder)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Comparative proteome analysis of human adenocarcinoma.
|
19381893 |
2010 |
|
Adenocarcinoma, Basal Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Diverse proteomic alterations in gastric adenocarcinoma.
|
15378696 |
2004 |
|
Adenocarcinoma, Oxyphilic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Diverse proteomic alterations in gastric adenocarcinoma.
|
15378696 |
2004 |